The All India Institute of Medical Sciences is toying with the idea to conduct a clinical trial of the plasma therapy for COVID-19 treatment and preparations are on for the same, AIIMS Director Dr Randeep Guleria said on Tuesday.
A PTI report quoting the official sources said the modalities of taking the approvals from the Drug Controller General of India (DCGI) is being worked out.
Stating that the mode of treatment in COVID-19 is still at an “experimental stage”, Gleria stressed on the need to have good and well conducted research trials before its benefit and this mode of therapy can be recommended for routine use in coronavirus patients.
“AIIMS is working with the ICMR to conduct a clinical trial on the efficacy of convalescent plasma therapy in COVID-19 patients,” he said as stated by the report.
The doctor said it is necessary for all institutes to take necessary approvals from the Indian Council of Medical Research (ICMR) and DCGI and follow proper clinical practice guidelines for this research.
“In very limited studies, globally, convalescent plasma as an adjunct to other supportive therapies and treatments has shown some benefit in the management of severe patients of COVID-19,” Guleria said.
He also underlined that plasma has to be tested for its safety and it should have sufficient antibodies to be useful for giving it to COVID-19 patients.
“Giving plasma from a recovered patient without testing whether it has enough antibody titer or not may cause more harm than good as it can cause transfusion-related reactions,” he said.